Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Inclusion Criteria

• •1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
• •2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures including requesting that a participant fast for any laboratory evaluations.
• •3. Is a cytochrome P-450 (CYP)2C9, CYP2C19, and CYP2D6 extensive metabolizer, based on genotyping of pharmacogenomic (PGx) deoxyribonucleic acid (DNA) analysis.
• •4. Is a male or female aged 18 to 55 years, inclusive, at Screening.
• •5. Weighs at least 50 kilogram (kg) and has a body mass index (BMI) of 18.0 to 30 kilogram per square meter (kg/m\^2), inclusive, at Screening and Check-in (Day -1).
• •6. The healthy control participants in Part 1 of this study will be matched at Day-1 with the UC or CD participants in Group 1 or 3 (whichever enrolls faster) on the basis of age (+/-10 years), gender and weight (+/-30 \[percent\] %).
• •7. Participants in Part 2 and Group 1 will be matched on Day-1 on the basis of the inflammatory bowel disease (IBD) diagnosis (UC or CD), age (+/-10 years), gender and weight (+/-30%).
• •For Part 1 Participants:
• •8. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study.
• •9. All female participants who are of childbearing potential and who are sexually active, agree to routinely use adequate contraception from signing of informed consent throughout the duration of the study. NOTE: Female participants NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation \[at least 2 years post-operation\]) or who are postmenopausal (example, defined as at least 1 year since last regular menses with an follicle stimulated hormone \[FSH\] greater than \[\>\] 40 international units per liter \[IU/L\] or at least 5 years since last regular menses, confirmed before any study medication is implemented).
• •For Part 1 Only Participants with UC or CD
• •10. Has a diagnosis of UC or CD established at least 6 months prior to enrollment by clinical and endoscopic evidence and corroborated by a histopathology report.
• •11. Prior to entering the study, participants with UC must have had an endoscopy during screening to confirm active disease, with Mayo score of 6 to 12 and an endoscopic subscore greater than or equal to (\>=)2. Participants with CD must have a Crohn's Disease Activity Index (CDAI) score of 220 to 450 to confirm moderate to severe disease on entry (that is, Day-1).
• •12. Participant may be receiving a therapeutic dose of the following drugs for treatment of their underlying disease:
• •* Oral or topical 5-aminosalicylic acid (5-ASA) compounds provided that the dose has been stable for the 2 weeks immediately prior to enrollment.
• •* Probiotics (example, Culturelle, Saccharomyces boulardii) provided that the dose has been stable for the 2 weeks immediately prior to enrollment.
• •* Antidiarrheals (example, loperamide, diphenoxylate with atropine) for control of chronic diarrhea.
• •* Azathioprine or 6-mercaptopurine, provided that the dose has been stable for the 8 weeks immediately prior to enrollment.
• •* Methotrexate provided that the dose has been stable for the 8 weeks immediately prior to randomization.
• •* Oral corticosteroid therapy (prednisone at a stable dose less than or equal to \[\<=\] 30 milligram per day \[mg/day\], or equivalent steroid) provided that the dose has been stable for the 4 weeks immediately prior to enrollment, if corticosteroids have been initiated, or for the 2 weeks immediately prior to the enrollment, if corticosteroids are being tapered.
• •13. C-reactive protein (CRP) \>=5 milligram per liter (mg/L) during screening period in participants with CD.
• •For Part 1 Healthy Participants Only:
• •14. The participant, in opinion of the investigator, is in healthy condition as determined by a prestudy physical examination, medical history, vital signs, electrocardiogram (ECG), and the results of blood biochemistry, hematology, serology, and urinalysis tests.
• •For Part 2 Participants with Active UC and CD:
• •15. A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from signing of informed consent throughout the duration of the study and for 57 days after last dose.
• •16. All female participants who are of childbearing potential and who are sexually active with a nonsterilized male partner, agree to routinely use adequate contraception from Screening until 57 days after receiving the last dose of study medication. NOTE: Female participants NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation \[at least 2 years post-operation\]) or who are postmenopausal (example, defined as at least 1 year since last regular menses with an FSH \>40 IU/L or at least 5 years since last regular menses, confirmed before any study medication is implemented.
• •17. Has a diagnosis of UC or CD established at least 6 months prior to enrollment by clinical and endoscopic evidence and corroborated by a histopathology report.
• •18. Is on established vedolizumab intravenous (IV) for treatment of UC or CD and is in clinical remission as assessed within 7 days of dosing defined for UC; A complete Mayo score of \<=2 points and no individual subscore \>1 point. For CD; CDAI of \<=150 points.
• •19. Participant may be receiving a therapeutic dose of the following drugs for treatment of their underlying disease:
• •* Oral or topical ASA compounds provided that the dose has been stable for the 2 weeks immediately prior to enrollment.
• •* Probiotics (example, Culturelle, S. boulardii) provided that the dose has been stable for the 2 weeks immediately prior to enrollment.
• •* Antidiarrheals (eg, loperamide, diphenoxylate with atropine) for control of chronic diarrhea.
• •* Azathioprine or 6-mercaptopurine, provided that the dose has been stable for the 8 weeks immediately prior to enrollment.
• •* Methotrexate provided that the dose has been stable for the 8 weeks immediately prior to randomization.
• •* Oral corticosteroid therapy (prednisone at a stable dose \<30 mg/day, or equivalent steroid) provided that the dose has been stable for the 4 weeks immediately prior to enrollment if corticosteroids have been initiated or for the 2 weeks immediately prior to the enrollment if corticosteroids are being tapered.